CN | EN

首页 > News & Information > Enterprise News >

Xinruilihong and J&J (Janssen Diagnostics Department) Achieved a Strategic Cooperation, and J&J CellSearch® CTC Detection Will Provide Comprehensive Service in Clinical and Scientific Research Fields

source:未知 2016-06-15

  J&J CellSearch® is the only commercial product in the world, which is approved by FDA and used for blood detection of circulating tumor cells (CTC) in the management of malignant tumor disease. Meanwhile, this product is the only product which is approved by CFDA for clinical diagnosis of CTC.
  Recently, “liquid biopsy” has become a hot topic in the field of precision medical. As a leader of CTC technology in “liquid biopsy”, J&J attracts tremendous attention. Tianjin Xinruilihong Medical Technology Co., Ltd, as a partner of J&J, adds clinical and research service based on J&J’s original CTC business which extends and expands J&J’s original CTC business.
  Xinruilihong is the first platform in China that provides vertical detection of medical services connecting clinical doctor and medical laboratory based on O2O model. The platform can accurately distinguish disease fields and provide accurate detection analysis for disease-related projects. The platform combines IVD reagent sale, independent third-party medical laboratory and channel operating together, and provides more tumor patients with convenient precise medical testing service. Xinruilihong has carried out “liquid biopsy” detection, and provides clinicians with reasonable and accurate basis of companion diagnosis and research data.
  The cooperation of Xinruilihong and J&J (Janssen Diagnostics Department) mainly due to the adjustment of the J&J’s strategic layout. J&J (Janssen Diagnostics Department) began to seek external partners and made preparation for China lab projects since 2014. This adjustment aimed at extending service business on the basis of original sales business, and utilized channel operation and third-party lab providing precise CellSearch® CTC testing service to cancer patients. According to this cooperation background, Xinruilihong with its innovative and efficient operation platform reached an exclusive cooperation with J&J (Janssen Diagnostics Department).
  After several negotiations and careful arrangements, “Xinruilihong & J&J CellSearch ® CTC lab project launch meeting” was held successfully in March of 2016. During April and May in 2016. Top executives of global Janssen Diagnostics Department visited Tianjin along with their team and they praised the progress of the Xinruilihong lab project. They hoped that both parties could have a deeper and long-term cooperation in the future.

Sales Director (Europe, Middle East, Africa and China) of J&J (Janssen Diagnostics Department) Tim Pitfield with his team in Apr.13rd, 2016

Chief Medical Officer of J&J (Janssen Diagnostics Department) Global Mr Jorge with his team in May 18th, 2016
  Many research data, whether stable performance, automatic operation and global large-sample clinical data, confirmed that J&J CellSearch® CTC technology is the unique reliable and credible technology in currently CTC field, and standard of CTC detection.
  For the cooperating in scientific research, Xinruilihong is actively negotiating with J&J (Janssen Diagnostics Department) for importing a series of advanced research tools into China. These tools will support more research projects, including some common concerned technologies like cell enrichment, molecular analysis and etc. Xinruilihong and J&J will cooperate closely to carry out more complementary business and serve more cancer patients in China.
  With the spirit of open, cooperation and innovation, Xinruilihong welcomes more like-minded enterprises to join us, and we’d like to integrate resources together and share channels together. Xinruilihong relies on the vertical detection platform, bases on projects and has courage to explore. We develop both upstream and downstream business, actively expand excellent high-end projects for upstream, deepen and strengthen the channel advantages for downstream, and promote the development of precision diagnosis and treatment business.
  Till now, Xinruilihong has built the vertical testing services platform and WeChat platform using the internet technology. This platform is able to realize a series of services including online registration, application, payment, query, popularization of science, download and other functions. After testing application submitted, our specialist will contact guest and inform them going to the nearest medical institution to take samples. Within 5days after delivering, the guest will obtain a electronic or paper test result.

Back